Illumina Paying up to $90M in Cash and Stock in Epicentre Acquisition

According to a filing with the Securities and Exchange Commission, Illumina acquired Epicentre for $60 million in cash as well as $15 million in stock that is "subject to forfeiture if certain non-revenue based milestones are not met." In addition, Illumina will pay up to $15 million in contingent considerations based on "certain revenue-based milestones" by Jan. 10, 2013.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.